Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Placebo-controlled, Randomized Dose Ranging Trial to Determine the Safety and Efficacy of Three Dose Levels of EMA401 in Reducing 24-hour Average Pain Intensity Score in Patients With Post-herpetic Neuralgia

Trial Profile

A Double-blind, Placebo-controlled, Randomized Dose Ranging Trial to Determine the Safety and Efficacy of Three Dose Levels of EMA401 in Reducing 24-hour Average Pain Intensity Score in Patients With Post-herpetic Neuralgia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2019

At a glance

  • Drugs Olodanrigan (Primary)
  • Indications Neuropathic pain; Postherpetic neuralgia
  • Focus Therapeutic Use
  • Acronyms EMPHENE
  • Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 27 Nov 2018 Planned End Date changed from 4 Sep 2019 to 28 Aug 2020.
    • 27 Nov 2018 Planned primary completion date changed from 28 Aug 2019 to 21 Aug 2020.
    • 02 Oct 2018 Planned primary completion date changed from 4 Sep 2019 to 28 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top